Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05502900

Adjuvant Melatonin for Uveal Melanoma (AMUM)

Adjuvant Melatonin for Uveal Melanoma: A Randomized Open Phase III Study

Sponsor: Gustav Stalhammar

Conditions Eye Cancer, Intraocular Melanoma Uveal Melanoma Uveal Melanoma, Posterior, Medium/Large Size

Interventions Melatonin

Updated 6 times since 2022 Last updated: May 12, 2025 Started: Oct 2, 2022 Primary completion: Jan 1, 2031 Completion: Jan 1, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Eye Cancer, Intraocular Melanoma and Uveal Melanoma and is currently actively recruiting participants. Gustav Stalhammar leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Jun 2025 — Present [monthly]

Recruiting PHASE3
Sep 2024 — Jun 2025 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jul 2024 [monthly]

Recruiting PHASE3
Nov 2022 — Dec 2023 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Sep 2022 — Nov 2022 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gustav Stalhammar
Karolinska Trial Alliance
Swedish Cancer Foundation
The Swedish Eye Foundation (Ögonfonden)
The Swedish Society of Medicine

Data source: St. Erik Eye Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stockholm, Sweden